Market Overview

UPDATE: Bank of America Raises PO to $130 on Alexion Pharmaceuticals on Soliris Data

Share:
Related ALXN
2 Key Reasons Morgan Stanley Upgraded Alexion Pharmaceuticals
Benzinga's Top Upgrades, Downgrades For May 25, 2017

Bank of America reiterated its Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN) and raised its price objective from $118 to $130.

Bank of America commented, "We are increasing our PO from $118 to $130 to reflect a higher probability of success for Soliris in neuromyelitis optica (NMO) following impressive Phase 2 data presented yesterday. We removed MG and the nondescript "other indications" for Soliris from our valuation, as current data suggests NMO may be the final large indication beyond PNH and aHUS (STEC and AMR incremental drivers)."

Alexion Pharmaceuticals closed at $111.30 on Tuesday.

Latest Ratings for ALXN

DateFirmActionFromTo
May 2017Morgan StanleyUpgradesEqual-WeightOverweight
Mar 2017UBSInitiates Coverage OnBuy
Mar 2017NomuraInitiates Coverage OnBuy

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (ALXN)

View Comments and Join the Discussion!